Status:
UNKNOWN
Validation Study of a Serum-miRNA Signature in Glioma Patients.
Lead Sponsor:
Regina Elena Cancer Institute
Collaborating Sponsors:
Azienda Ospedaliero Universitaria di Sassari
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Conditions:
Biomarker
Eligibility:
All Genders
18+ years
Brief Summary
Prospective, multicenter, noninterventional, nonprofit study of a cohort of patients with glioma, aimed at validating miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, spe...
Detailed Description
Scientific data suggest that a serum signature of miRNA could be a promising noninvasive diagnostic and prognostic tool for stratify, by liquid biopsy, patients with glioma according to IDH1 status. I...
Eligibility Criteria
Inclusion
- histological diagnosis of glioma;
- age≥18 years;
- No other primary tumor;
- No metastatic disease
- Informed consent on treatment and molecular analysis
Exclusion
- Histological diagnosis of non-glial tumor;
- age\< 18;
- patients with concomitant other solid tumors
- metastatic disease; HIV seropositivity.
Key Trial Info
Start Date :
May 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 10 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06178692
Start Date
May 10 2020
End Date
May 10 2024
Last Update
December 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Regina Elena" National Cancer Institute
Rome, Italy, 00144